Pain Biomarkers in Cancer: An Overview.
C-reactive protein
Cancer pain
analgesia
biomarkers
pain diagnosis
pro-inflammatory cytokines
Journal
Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
04
2020
accepted:
09
08
2020
pubmed:
4
11
2020
medline:
27
4
2021
entrez:
3
11
2020
Statut:
ppublish
Résumé
Pain is a common symptom in oncologic patients and its management is generally guided with reference to pain individually perceived by patients and expressed through self-reported scales. However, the utility of these tools is limited as it strongly depends on patients' opinions. For this reason, more objective instruments are desirable. In this overview, scientific articles indicating potential markers to be used for pain management in cancer were collected and discussed. Research was performed on principal electronic scientific databases by using the words "pain", "cancer", "markers" and "biomarkers" as the main keywords, and findings describing potential biomarkers for the management of cancer pain were reported. Studies on pain markers not specific for cancer typology (inflammatory, genetic markers predicting response to analgesic drugs, neuroimaging markers) and pain markers for specific types of cancer (bone cancer, breast cancer, lung cancer, head and neck cancer, prostate cancer, cancer in pediatrics) have been presented and commented on. This overview supports the view of the involvement of inflammatory mediators in the mechanisms underlying cancer pain. Only a small amount of data from research up till today is available on markers that can help in the management of pain, except for pro-inflammatory cytokines and other inflammatory indexes such as C-reactive protein (CRP). However, biomarkers are a promising strategy useful to predict pain intensity and to objectively quantify analgesic response in guiding decisions regarding individual-tailored treatments for cancer patients.
Sections du résumé
BACKGROUND
Pain is a common symptom in oncologic patients and its management is generally guided with reference to pain individually perceived by patients and expressed through self-reported scales. However, the utility of these tools is limited as it strongly depends on patients' opinions. For this reason, more objective instruments are desirable.
OBJECTIVE
In this overview, scientific articles indicating potential markers to be used for pain management in cancer were collected and discussed.
METHODS
Research was performed on principal electronic scientific databases by using the words "pain", "cancer", "markers" and "biomarkers" as the main keywords, and findings describing potential biomarkers for the management of cancer pain were reported.
RESULTS
Studies on pain markers not specific for cancer typology (inflammatory, genetic markers predicting response to analgesic drugs, neuroimaging markers) and pain markers for specific types of cancer (bone cancer, breast cancer, lung cancer, head and neck cancer, prostate cancer, cancer in pediatrics) have been presented and commented on.
CONCLUSION
This overview supports the view of the involvement of inflammatory mediators in the mechanisms underlying cancer pain. Only a small amount of data from research up till today is available on markers that can help in the management of pain, except for pro-inflammatory cytokines and other inflammatory indexes such as C-reactive protein (CRP). However, biomarkers are a promising strategy useful to predict pain intensity and to objectively quantify analgesic response in guiding decisions regarding individual-tailored treatments for cancer patients.
Identifiants
pubmed: 33138755
pii: CPD-EPUB-111067
doi: 10.2174/1381612826666201102103520
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Inflammation Mediators
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
293-304Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.